News
Goldman Sachs stock rises 20% YTD, outpacing the S&P 500. Analysts suggest holding GS due to its high momentum but caution on ...
Under [the plaintiffs'] reading, virtually all pharmaceutical product-support services would qualify as a kickback,” U.S.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback